Table 1 Common treatment-related adverse events*

From: Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial

Adverse event

Any grade, no. (%)

Grade ≥3, no. (%)

Any causally related event

7/12 (58)

3/12 (25)

Nausea

3/12 (25)

0

Fatigue

4/12 (33)

0

Diarrhea

3/12 (25)

0

Dysgeusia

2/12 (17)

0

Colitis

0

1/12 (8)

Hyperglycemia

0

1/12 (8)

Generalized muscle weakness

0

1/12 (8)

  1. *In at least two patients.